XML 75 R60.htm IDEA: XBRL DOCUMENT v3.20.4
Collaboration and License Agreements (Details)
$ in Thousands, € in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Mar. 31, 2020
USD ($)
Feb. 28, 2019
USD ($)
Oct. 31, 2018
USD ($)
Nov. 30, 2017
USD ($)
Oct. 31, 2017
USD ($)
Aug. 31, 2016
USD ($)
Nov. 30, 2015
USD ($)
milestone
Oct. 31, 2014
USD ($)
Oct. 31, 2014
EUR (€)
Sep. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Collaboration and License Agreements [Abstract]                          
Sanofi Upfront Payment             $ 300,000            
Sanofi Development Milestones             $ 110,000            
Number of development milestones | milestone             4            
Sanofi Regulatory Milestones             $ 220,000            
Number of regulatory milestones | milestone             4            
Sanofi Outcomes Study Milestone             $ 100,000            
Sanofi Sales Milestone Payments             $ 990,000            
Number of commercial milestones | milestone             6            
Royalties percentage             40.00%            
Funded commercialization costs             40.00%            
Development costs period             3 years            
Sanofi Development Costs Funded by Lexicon Maximum Amount             $ 100,000            
Expiration period             10 years            
Sanofi Revenue Allocated to Development Deliverable             $ 113,800            
Sanofi Revenue Allocated to License Deliverable             126,800            
Sanofi Revenue Recognized                       $ 286,000 $ 33,200
Sanofi Revenue Allocated to Funding Deliverable             $ 59,400            
Ipsen Total Payments To Date                     $ 47,200    
Ipsen Total Upfront Payments               $ 24,500          
Ipsen Milestone Payment Received   $ 2,300 $ 1,300 $ 3,800 $ 3,800 $ 6,400       $ 5,100      
Ipsen Revenue Allocated to License Deliverable               21,200       1,400  
Ipsen Maximum Regulatory And Commercial Milestones               9,600          
Ipsen Revenue Allocated to Development Deliverable               1,700          
Ipsen Revenue Allocated to Committee Deliverable               $ 100          
Ipsen Revenue Recognized                     300 4,900 $ 4,600
Ipsen product sales                     1,300 $ 1,600  
Ipsen Maximum Sales Milestones | €                 € 72        
Settlement Payment from Termination                     208,000    
Sanofi Termination Agreement                     260,000    
Sanofi Deferred Revenue from Termination                     23,500    
Subsequent Event [Line Items]                          
Settlement Payment from Termination                     $ 208,000    
Subsequent Event                          
Collaboration and License Agreements [Abstract]                          
Settlement Payment from Termination $ 26,000                        
Subsequent Event [Line Items]                          
Settlement Payment from Termination $ 26,000